Loading
Everything OnCo dates to 1998: 62 entries, 20 landmarks, 13 approvals, 9 companies founded and 8 papers. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
62 dated entries in OnCo fall in 1998: 20 landmarks, 13 approvals, 9 companies founded, 8 papers, 6 papers listed on people's pages, 3 journals founded, 1 technology, 1 trial reported and 1 regulatory event.
Of those, 1 to the day and 61 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Metastatic melanoma
Metastatic breast cancer after anthracycline and taxane; later adjuvant and metastatic colorectal cancer, rectal chemoradiotherapy
Osteoarthritis and rheumatoid arthritis pain (oncology use in metronomic regimens is off-label)
NSCLC with cisplatin
HercepTest: HER2 overexpression to select trastuzumab in breast cancer (first companion diagnostic)
Sickle cell anaemia (Droxia)
Genital warts, superficial basal cell carcinoma and actinic keratosis (Aldara)
Relief of bone pain from multiple painful osteoblastic skeletal metastases (Quadramet)
Risk reduction in high-risk women
Erythema nodosum leprosum
Adjunctive diagnostic tool for thyroglobulin testing in well-differentiated thyroid cancer; pre-therapeutic stimulation for radioiodine remnant ablation added 2007
HER2+ metastatic breast cancer
Intravesical therapy of BCG-refractory carcinoma in situ of the bladder when immediate cystectomy is not acceptable
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
HER2+ metastatic breast cancer: first targeted antibody for a solid tumour
The year reported on trial records, with the headline result the record gives.
5-year locoregional control 49% (nimorazole) vs 33% (placebo).
The publication year on key paper records.
Overgaard J, Hansen HS, Overgaard M, et al. Radiotherapy and Oncology.
Fraass B, Doppke K, Hunt M, et al. Medical physics.
Coffey MC, Strong JE, Forsyth PA, Lee PW. Science.
D'Amico AV, Whittington R, Malkowicz SB, et al. JAMA.
Hirota S, Isozaki K, Moriyama Y, et al. Science.
Duesberg P, Rausch C, Rasnick D, et al. Proceedings of the National Academy of Sciences.
Herman JG, Umar A, Polyak K, et al. Proceedings of the National Academy of Sciences.
Al-Sarraf M, LeBlanc M, Giri PG, et al. Journal of Clinical Oncology.
The history entries editors wrote on cancer records: the dated turning points of each disease.
HR-positive / HER2-negative breast cancer
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Journal of the National Cancer Institute report that codeleted anaplastic oligodendrogliomas respond to PCV and live longer.
High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)
High-risk early HR-positive breast cancer
Advanced melanoma (unresectable stage III and stage IV)
KIT exon 11-mutant GIST
Chronic myeloid leukaemia (CML). Druker's phase 1 trial of STI571: complete haematologic responses in nearly every chronic-phase patient.
Chronic myeloid leukaemia, chronic phase
Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)
Nasopharyngeal carcinoma
Gastrointestinal stromal tumour (GIST)
Sarcomas (soft tissue, bone, GIST)
Acute myeloid leukaemia in children
Placental-site trophoblastic tumour and epithelioid trophoblastic tumour
Atypical teratoid/rhabdoid tumour (ATRT). Versteege and colleagues (Nature) find biallelic loss, the first chromatin-remodelling tumour suppressor.
Colorectal cancer. MLH1 promoter hypermethylation explains most sporadic microsatellite-unstable cancers and is reversible in the laboratory.
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
HER2-low and HER2-ultralow metastatic breast cancer
HER2-positive breast cancer. First antibody for a solid tumour; OS benefit with chemotherapy.
Early HER2-positive breast cancer
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
France (seat not stated)
Gaithersburg, MD
San Diego, CA
Munich
Seoul
Norwalk, CT
New York, NY
South Plainfield, NJ
South San Francisco, CA
The founded year on journal records.
Elsevier
Springer (Springer Japan)
Editorial Board of the Chinese Journal of Lung Cancer (Chinese Anti-Cancer Association and Chinese Antituberculosis Association)
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Psycho-Oncology
JAMA
Journal of Clinical Oncology
Cancer
Journal of Clinical Oncology
Annual Review of Genetics